These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18489402)

  • 1. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection.
    Reiberger T; Rasoul-Rockenschaub S; Rieger A; Ferenci P; Gangl A; Peck-Radosavljevic M
    Eur J Clin Invest; 2008 Jun; 38(6):421-9. PubMed ID: 18489402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
    Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
    J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA; Gutiérrez-Valencia A; Gil Ide L; Merino D; Rivero A; Ríos-Villegas MJ; Delgado M; González-Serrano M; Collado A; Torres-Tortosa M; Omar M; López-Ruz MA; Macías J; Arponen S; Pineda JA
    Clin Infect Dis; 2009 Oct; 49(8):e84-91. PubMed ID: 19772388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.
    Duvoux C; Villamil F; Renner EL; Grazi GL; Firpi RJ; Pageaux G; Mulhaupt B; Schirm F; Rauer B; Bernhardt P; Levy G
    Ann Transplant; 2015 Jan; 20():25-35. PubMed ID: 25588713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hepatitis C in HIV infected and other immunocompromised individuals.
    Seth AK
    Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.
    Farnik H; Zimmermann T; Herrmann E; Bechstein WO; Kronenberger B; Galle PR; Labocha S; Ferreiros N; Geisslinger G; Zeuzem S; Sarrazin C; Welker MW
    Liver Int; 2015 Jan; 35(1):176-83. PubMed ID: 24649882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF; Sun HQ; Huang Q; Wang JR; Zhang XX; Liu XN; Ma Q; Lu HZ
    Haemophilia; 2010 May; 16(3):502-7. PubMed ID: 20028427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
    J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.